These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
420 related articles for article (PubMed ID: 28371907)
1. Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Blumenthal DT; Gorlia T; Gilbert MR; Kim MM; Burt Nabors L; Mason WP; Hegi ME; Zhang P; Golfinopoulos V; Perry JR; Hyun Nam D; Erridge SC; Corn BW; Mirimanoff RO; Brown PD; Baumert BG; Mehta MP; van den Bent MJ; Reardon DA; Weller M; Stupp R Neuro Oncol; 2017 Aug; 19(8):1119-1126. PubMed ID: 28371907 [TBL] [Abstract][Full Text] [Related]
2. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389 [TBL] [Abstract][Full Text] [Related]
3. Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525. Bell EH; Pugh SL; McElroy JP; Gilbert MR; Mehta M; Klimowicz AC; Magliocco A; Bredel M; Robe P; Grosu AL; Stupp R; Curran W; Becker AP; Salavaggione AL; Barnholtz-Sloan JS; Aldape K; Blumenthal DT; Brown PD; Glass J; Souhami L; Lee RJ; Brachman D; Flickinger J; Won M; Chakravarti A JAMA Oncol; 2017 Jun; 3(6):784-792. PubMed ID: 28097324 [TBL] [Abstract][Full Text] [Related]
4. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. Gramatzki D; Kickingereder P; Hentschel B; Felsberg J; Herrlinger U; Schackert G; Tonn JC; Westphal M; Sabel M; Schlegel U; Wick W; Pietsch T; Reifenberger G; Loeffler M; Bendszus M; Weller M Neurology; 2017 Apr; 88(15):1422-1430. PubMed ID: 28298550 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma. Wang Y; Chen X; Zhang Z; Li S; Chen B; Wu C; Wang L; Zhang X; Wang J; Chen L; Jiang T Neurosurg Rev; 2014 Jan; 37(1):73-8. PubMed ID: 23912878 [TBL] [Abstract][Full Text] [Related]
8. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840 [TBL] [Abstract][Full Text] [Related]
9. The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma. Park CK; Lee SH; Kim TM; Choi SH; Park SH; Heo DS; Kim IH; Jung HW J Neurooncol; 2013 Apr; 112(2):277-83. PubMed ID: 23377829 [TBL] [Abstract][Full Text] [Related]
10. Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study. Franceschi E; Depenni R; Paccapelo A; Ermani M; Faedi M; Sturiale C; Michiara M; Servadei F; Pavesi G; Urbini B; Pisanello A; Crisi G; Cavallo MA; Dazzi C; Biasini C; Bertolini F; Mucciarini C; Pasini G; Baruzzi A; Brandes AA; J Neurooncol; 2016 May; 128(1):157-162. PubMed ID: 26943851 [TBL] [Abstract][Full Text] [Related]
11. Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma. Hsieh SY; Chan DT; Kam MK; Loong HH; Tsang WK; Poon DM; Ng SC; Poon WS Hong Kong Med J; 2017 Dec; 23(6):594-8. PubMed ID: 28798282 [TBL] [Abstract][Full Text] [Related]
12. The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. Sher DJ; Henson JW; Avutu B; Hochberg FH; Batchelor TT; Martuza RL; Barker FG; Loeffler JS; Chakravarti A J Neurooncol; 2008 May; 88(1):43-50. PubMed ID: 18231723 [TBL] [Abstract][Full Text] [Related]
13. Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era. Paravati AJ; Heron DE; Landsittel D; Flickinger JC; Mintz A; Chen YF; Huq MS J Neurooncol; 2011 Aug; 104(1):339-49. PubMed ID: 21181233 [TBL] [Abstract][Full Text] [Related]
14. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. Carlson BL; Grogan PT; Mladek AC; Schroeder MA; Kitange GJ; Decker PA; Giannini C; Wu W; Ballman KA; James CD; Sarkaria JN Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):212-9. PubMed ID: 19695438 [TBL] [Abstract][Full Text] [Related]
17. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Minniti G; Amelio D; Amichetti M; Salvati M; Muni R; Bozzao A; Lanzetta G; Scarpino S; Arcella A; Enrici RM Radiother Oncol; 2010 Dec; 97(3):377-81. PubMed ID: 20855119 [TBL] [Abstract][Full Text] [Related]
18. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial. Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983 [TBL] [Abstract][Full Text] [Related]
19. Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma. Minniti G; Armosini V; Salvati M; Lanzetta G; Caporello P; Mei M; Osti MF; Maurizi RE J Neurooncol; 2011 Jul; 103(3):683-91. PubMed ID: 21052773 [TBL] [Abstract][Full Text] [Related]
20. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea. Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]